Literature DB >> 2436329

Characterization of four monoclonal antibodies to factor VIII coagulant protein and their use in immunopurification of factor VIII.

M P Croissant, H van de Pol, H H Lee, J P Allain.   

Abstract

Four monoclonal anti-VIII:C antibodies were obtained from the fusion of the splenocytes of one Balb/C mouse with a specific activity ranging from 2.3 to 45,000 U/mg when purified from ascitic fluid. Only one antibody was able to inhibit completely Factor VIII:C in normal plasma. The four antibodies could bind Factor VIII:CAg in plasma and commercial concentrate both in liquid and solid phase, and were suitable for immunopurification of Factor VIII:C. Three antibodies competed with polyclonal anti-VIII:CAg Fab' in a liquid phase IRMA, and all of them were able to displace their own binding to Factor VIII:CAg. Competition studies between monoclonal antibodies for the binding to Factor VIII:CAg were performed and showed the recognition of different epitopes and various functional impact. These studies indicate that at least one antibody, with the lowest anti-VIII:C titer clearly recognizes a different epitope of VIII:C than those recognized by the others. Affinity constants ranged from 10(9) to 10(10) l/mole.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2436329

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

1.  First determination of the secondary structure of purified factor VIII light chain.

Authors:  N Bihoreau; M P Fontaine-Aupart; A Lehegarat; M Desmadril; J M Yon
Journal:  Biochem J       Date:  1992-11-15       Impact factor: 3.857

2.  Structural and functional characterization of Factor VIII-delta II, a new recombinant Factor VIII lacking most of the B-domain.

Authors:  N Bihoreau; P Paolantonacci; C Bardelle; M P Fontaine-Aupart; S Krishnan; J Yon; J L Romet-Lemonne
Journal:  Biochem J       Date:  1991-07-01       Impact factor: 3.857

3.  Product-dependent anti-factor VIII antibodies.

Authors:  S Butenas; J Krudysz-Amblo; G E Rivard; K G Mann
Journal:  Haemophilia       Date:  2013-04-04       Impact factor: 4.287

4.  Tolerance to factor VIII inhibitors in hemophilia A patients: a French twist.

Authors:  V Pascual; J D Capra
Journal:  J Clin Invest       Date:  1996-03-15       Impact factor: 14.808

5.  Potency and mass of factor VIII in FVIII products.

Authors:  S Butenas; B Parhami-Seren; M T Gissel; E D Gomperts; D N Fass; K G Mann
Journal:  Haemophilia       Date:  2008-08-06       Impact factor: 4.287

6.  Evidence that a secondary binding and protecting site for factor VIII on von Willebrand factor is highly unlikely.

Authors:  S Layet; J P Girma; B Obert; E Peynaud-Debayle; N Bihoreau; D Meyer
Journal:  Biochem J       Date:  1992-02-15       Impact factor: 3.857

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.